Summary of findings 12. Fluoxetine compared to hypericum.
Fluoxetine compared to hypericum | ||||||
Patient or population: patients with depression Settings: in‐ and outpatients Intervention: fluoxetine Comparison: hypericum | ||||||
Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
Assumed risk | Corresponding risk | |||||
Hypericum | Fluoxetine | |||||
Failure to respond (reduction ≥ 50% on HDRS) |
490 per 1000 | 485 per 1000 (346 to 625) | OR 0.98 (0.55 to 1.73) | 717 (6 studies) | ⊕⊕⊕⊝ moderate1 | |
Endpoint score (HDRS or MADRS) |
The mean endpoint score in the intervention groups was 0.13 standard deviations higher (0.02 lower to 0.29 higher) | 648 (5 studies) | ⊕⊕⊕⊝ moderate1 | This corresponds to a very small effect according to conventions proposed by Cohen 1992 | ||
Failure to complete ‐ total ‐ | 129 per 1000 | 133 per 1000 (88 to 189) | OR 1.04 (0.65 to 1. 68) | 679 (5 studies) | ⊕⊕⊕⊝ moderate1 | |
Failure to complete ‐ inefficacy ‐ | OR 4.70 (0.22 to 99.39) | 401 (2 studies) | ⊕⊕⊕⊝ moderate1 | |||
Failure to complete ‐ side effects ‐ | 35 per 1000 | 42 per 1000 (20 to 88) | OR 1.21 (0.56 to 2.64) | 679 (5 studies) | ⊕⊕⊕⊝ moderate1 | |
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. |
1 Limitations in studies designs: no details on randomisation procedures and allocation concealment. Blinding stated but not tested.